Tirzepatide is a synthetic peptide supplied as a lyophilized powder for scientific and laboratory research applications, intended exclusively for analytical, experimental, and investigational research purposes only.
Specifications
| Compound | Tirzepatide 30mg |
|---|---|
| Category | Peptide |
| SKU | GRL-TIRZ-30 |
| Unit size | 30 mg |
| Price | $75.00 |
| Availability | In stock |
| Intended use | Laboratory research use only |
Compound identity
Reference facts for the compound itself, from PubChem (NIH). They describe the molecule, not a specific batch — batch purity is reported on the certificate of analysis.
| CAS Registry Number | 2023788-19-2 |
|---|---|
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813 g/mol |
| PubChem CID | 166567236 |
Tirzepatide 30mg is also written Tirzepatide peptide.
Research questions about this compound
How does the dual-agonist approach differ from single-receptor compounds?
The dual-agonist approach targets both GIP and GLP-1 receptors simultaneously, whereas traditional compounds typically target only the GLP-1 receptor . Research suggests this dual-receptor engagement may provide a synergistic effect on metabolic regulation, as evidenced by the weight loss outcomes observed in human trials [1, 2].
Is the weight loss observed in trials permanent?
The current human clinical trials, such as SURMOUNT-1, focus on the efficacy of the compound during the period of active administration . The SURMOUNT-1 trial evaluated weight change during 72 weeks of treatment; data regarding weight maintenance after cessation of the compound were not the primary focus of this study .
What is the significance of the animal model findings regarding thyroid tumors?
In animal models, specifically rodents, the administration of GLP-1 receptor agonists has been associated with an increased incidence of thyroid C-cell tumors . While this is a documented finding in these models, the clinical relevance to human physiology is still being evaluated by regulatory bodies and researchers .
Does the compound affect all individuals the same way?
Human trials demonstrate variability in individual response to the compound . While the mean results show significant weight reduction, the degree of response varies based on individual metabolic baselines and other physiological factors .
labels, lab notebooks, reorders
Tirzepatide 30mg — Reconstitution Calculator
For laboratory research use only. This tool computes the concentration of a reconstituted research solution and the volume that contains a target mass. Vial mass is a product specification, not a dose. It is not medical guidance and does not describe administration to humans or animals.
For laboratory research use only · not for human or animal use. Doses-per-bottle is pure arithmetic (vial mass ÷ target amount), not a dosing recommendation.
